Evidence map›Paper›PMID 33775400›Full record

ArticleMedicina clinica2021

[Frequency and predictive validity of olfactory and taste dysfunction in patients with SARS-CoV-2 infection].

Luis Ángel Pérula de Torres, Jesús González-Lama, Celia Jiménez García, Rosa Sánchez Montero, Faustino Rider Garrido, Yolanda Ortega López, Diego Pajares Conde, Miguel Ramírez Baena, Ignacio Párraga Martínez, Esperanza Romero-Rodríguez and 1 more

Abstract read
In one paragraph

Article in Medicina clinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luis Ángel Pérula de TorresInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía. Universidad de Córdoba, Córdoba, España; Unidad Docente Multiprofesional de Atención Familiar y Comunitaria de Córdoba, Córdoba, España; Grupo de Evaluación y Mejora del Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS-semFYC), Barcelona, España.
Jesús González-LamaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía. Universidad de Córdoba, Córdoba, España; Grupo de Evaluación y Mejora del Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS-semFYC), Barcelona, España; Centro de Salud «Matrona Antonia Mesa Fernández». UGC Cabra. AGS Sur de Córdoba, Córdoba, España.
Celia Jiménez GarcíaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía. Universidad de Córdoba, Córdoba, España; Distrito Sanitario Córdoba y Guadalquivir, Córdoba, España.
Rosa Sánchez MonteroDistrito Sanitario Córdoba y Guadalquivir, Córdoba, España.
Faustino Rider GarridoDistrito Sanitario Córdoba y Guadalquivir, Córdoba, España.
Yolanda Ortega LópezServicio de Medicina Preventiva. Hospital Infanta Margarita. AGS Sur de Córdoba, Córdoba, España.
Diego Pajares CondeServicio de Medicina Preventiva. Hospital Infanta Margarita. AGS Sur de Córdoba, Córdoba, España.
Miguel Ramírez BaenaServicio de Medicina Preventiva. Hospital Infanta Margarita. AGS Sur de Córdoba, Córdoba, España.
Ignacio Párraga MartínezSección de Investigación de la Sociedad Española de Medicina Familiar y Comunitaria (semFYC), Madrid, España; C.S. Zona viii de Albacete. Gerencia Atención Integrada de Albacete, Albacete, España; Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, España.
Esperanza Romero-RodríguezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía. Universidad de Córdoba, Córdoba, España; Grupo de Evaluación y Mejora del Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS-semFYC), Barcelona, España. Electronic address: espe_mrr@hotmail.com.
Grupo Colaborativo EPICOVID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveOlfactory and taste dysfunction (OD, TD) have been considered symptoms of SARS-CoV-2 infection. However, its presence in certain populations, especially those with mild clinical symptoms, has not been clarified. The objective was to estimate the frequency of OD and TD, and its predictive validity in patients detected in Primary Care. PATIENTS AND

methodsA cross-sectional study was carried out in the Spanish National Health System. An epidemiological survey was administered to patients who were requested the PCR test for SARS-CoV-2. Odds ratio (OR) were estimated to measure the magnitude of the association between OD and TD and the existence of SARS-CoV-2 infection. The sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of these symptoms in SARS-CoV-2 infection were calculated.

resultsOf 1,038 patients screened, 20.1% had SARS-CoV-2 infection. OD and DG were present in 64.4% (95% CI 56.0-72.1) and 56.2% (95% CI 47.9-64.2) of the subjects with infection, respectively. The OR for OD was 12.2 (95% CI 8.26-18.06) and for TD was 7.95 (95% CI 5.48-11.53). TD presented a sensitivity of 41.1% (95% CI 34.4-46.1), a specificity of 91.9% (95% CI 89.8-93.7), a PPV of 56.2% (95% CI48.0-64.2) and a NPV of 86.1% (95% CI 83.6-88.3), while the OD showed a sensitivity of 45.0% (95% CI 37.6-51.5), a specificity of 93.7% (95% CI 91.8-95.0), a PPV of 64.4% (95% CI 56.0-72.1) and a NPV of 87.1% (95% CI 84.7-89.2).

conclusionsMore than half of the subjects with SARS-CoV-2 infection have OD or TD. The presence of OD or TD could be of diagnostic utility due to its ability to predict infection in more than half of the cases.

Indexed as

COVID-19SARS-CoV-2Cross-Sectional StudiesHumansSmellTaste DisordersCOVID-19Disfunción olfatoriaDisgeusiaDysgeusiaOlfaction disordersSARS-CoV-2

Identifiers

PMID33775400
PMCPMC7843111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.